In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Hollings Cancer Center researchers have identified one reason why triple-negative breast cancer becomes resistant to ...

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative ...

Black women are more likely than white women to die from even the most treatable types of breast cancer, a study published ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...